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Review

Alport Syndrome Classiﬁcation and Management
Bradley A. Warady, Rajiv Agarwal, Sripal Bangalore, Arlene Chapman, Adeera Levin,
Peter Stenvinkel, Robert D. Toto, and Glenn M. Chertow
Alport syndrome affects up to 60,000 people in the United States. The proposed reclassiﬁcation of thin
basement membrane nephropathy and some cases of focal segmental glomerulosclerosis as Alport
syndrome could substantially increase the affected population. The reclassiﬁcation scheme categorizes
Alport syndrome as 3 distinct diseases of type IV collagen α3/4/5 based on a genetic evaluation: Xlinked, autosomal, and digenic. This approach has the advantage of identifying patients at risk for
progressive loss of kidney function. Furthermore, the shared molecular cause of Alport syndrome and
thin basement membrane nephropathy arises from mutations in the COL4A3, COL4A4, and COL4A5
genes, which contribute to downstream pathophysiologic consequences, including chronic kidney
inﬂammation. Recent evidence indicates that chronic inﬂammation and its regulation through antiinﬂammatory nuclear factor erythroid 2–related factor 2 (Nrf2) and proinﬂammatory nuclear factor
κ-light-chain-enhancer of activated B cells (NF-κB) transcription factors plays a central role in renal
tubular and glomerular cell responses to injury. Crosstalk between the Nrf2 and NF-κB pathways is
important in the regulation of inﬂammation in patients with chronic kidney disease; moreover, there is
evidence that an insufﬁcient Nrf2 response to inﬂammation contributes to disease progression. Given
the association between type IV collagen abnormalities and chronic inﬂammation, there is renewed
interest in targeted anti-inﬂammatory therapies in Alport syndrome and other forms of progressive
chronic kidney disease.

INTRODUCTION
Alport syndrome is a hereditary kidney disease characterized by structural abnormalities and dysfunction in the
glomerular basement membrane (GBM), as well as basement membranes of other tissues including the eye and
ear. Patients with Alport syndrome often experience progressive loss of kidney function with distinctive ultrastructural changes in the GBM, sensorineural hearing loss,
and variable ocular abnormalities.1 The GBM is the extracellular matrix (ECM) component of the selectively
permeable glomerular filtration barrier, which serves as a
critical barrier to the passage of blood cells and proteins
from the blood to the urinary space.2,3 This sheet-like ECM
is composed of 4 major macromolecules: laminin, type IV
collagen, nidogen, and heparan sulfate proteoglycan
(agrin). Type IV collagen is crucial for basement membrane stability4 and comprises w50% of the total GBM
protein mass.3 There are 6 genetically distinct α1 to α6
type IV collagen chains that assemble to form 3 unique
heterotrimers, α1α1α2, α3α4α5, and α5α5α6.3
In Alport syndrome, mutations in the COL4A3, COL4A4, or
COL4A5 genes result in defective type IV collagen α3, α4, or
α5 chains, respectively.5,6 Histologic lesions, including GBM
thinning and variable segmental GBM thickening and splitting, result from type IV collagen α-chain mutations and in
many cases result in a basket weave appearance rather than
the typical ribbon-like morphology when viewed on electron
microscopy (Fig 1).7-11 These structural abnormalities result
in a dysfunctional GBM leading to both hematuria and proteinuria, with downstream pathophysiologic consequences
including chronic inflammation and eventual fibrosis.3,9 Due
to the relationship between type IV collagen abnormalities
and kidney inflammation and fibrosis, there is growing
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relevance for targeted anti-inflammatory therapies in Alport
syndrome and other forms of progressive chronic kidney
disease (CKD).
UPDATE ON THE GENETICS AND PREVALENCE
OF ALPORT SYNDROME
The prevalence of Alport syndrome is estimated at
approximately 1 in 50,000 live births.12 Alport syndrome
affects an estimated 30,000 to 60,000 persons in the
United States.13 Based on the current classification scheme,
Alport syndrome accounts for an estimated 3% of CKD in
children and 0.2% of adults with end-stage kidney disease
(ESKD) in the United States.13 Alport syndrome is the
second most common monogenic cause of CKD after
autosomal dominant polycystic kidney disease.9 However,
based on a proposed reclassification by the Alport Syndrome Classification Working Group, the number of
affected persons with Alport syndrome may be greater
than currently estimated. The Working Group recommends reclassifying genetic diseases of type IV collagen as
Alport syndrome, including thin basement membrane
nephropathy (TBMN). Evidence suggests that a sizeable
fraction of patients with otherwise uncharacterized CKD or
those with focal segmental glomerulosclerosis (FSGS)
diagnosed based on histology have genetic abnormalities
in type IV collagen.11,14
Our understanding of the genetics of Alport syndrome
has evolved in recent years.15 The prevailing view is that
Alport syndrome is transmitted in an X-linked manner in
most cases. Under this assumption, an affected father could
not transmit the disease to his son.13 The X-linked mutation is seen in the COL4A5 gene.13 Pathogenic mutations in
639
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Figure 1. COL4A3, COL4A4, and COL4A5 mutations cause dysfunctional glomerular basement membrane (GBM) in Alport syndrome.10,11 Kidney biopsy specimens from a patient with Alport syndrome, a patient without Alport syndrome, and a patient with a thin
membrane lesion demonstrate that the GBM in patients with Alport syndrome is abnormally split and laminated compared with the
GBM of patients with other conditions. In patients with a thin basement membrane lesion, which is now proposed to be considered
as Alport syndrome, the GBM is abnormally thin. Images used with permission from UNC Kidney Center. www.unckidneycenter.org.
Accessed April 20, 2020.

COL4A3 and COL4A4 can also cause Alport syndrome, and
their transmission is autosomal.13
From analyses of the gnomAD and BRAVO databases, 2
large repositories of whole genome sequencing, Lanktree
et al16 reported that the prevalence of truncating mutations
per 100,000 individuals was 5 for COL4A5, 76 for COL4A4,
and 115 for COL4A3. Truncating mutations are a fraction of
the total mutations. Based on data from the Leiden Open
Variation Database, it can be estimated that truncating mutations make up 22.8% of COL4A5, 43.3% of COL4A4, and
24.1% of COL4A3 mutations. Thus, the estimated prevalence
of all mutations that could potentially lead to Alport syndrome
per 100,000 individuals is 21.9 for COL4A5, 175 for COL4A4,
and 477 for COL4A3.16-19 Although the prevalence of COL4A4
and COL4A3 mutations is several times higher than the more
widely recognized X-linked COL4A5 mutation, >15% of
persons with autosomal dominant mutations may develop
clinical manifestations of Alport syndrome.11,20-24 Taken
together, persons carrying the COL4A4 and COL4A3 mutations
may account for more cases of Alport syndrome than the Xlinked variant despite X-linked Alport syndrome having 100%
penetrance in men. Although autosomal dominant Alport
syndrome is currently considered rare and X-linked Alport is
still considered to account for most clinically apparent Alport
syndrome cases by experts, with new sequencing technologies, the prevalence of all COL4A mutations (including what
might be characterized as autosomal dominant Alport syndrome) in the population may be much higher than previously appreciated. Further studies are needed to ascertain the
true prevalence of the autosomal dominant form of Alport
syndrome and to better characterize the clinical implications
of individual mutations.
640

RISK FOR DISEASE PROGRESSION IN
ALPORT SYNDROME
The natural history of Alport syndrome is variable and is
informed by genetics and environmental factors. The
former are better studied and include large deletions,
nonsense mutations, and small mutations affecting reading
frames that result in lower or absent levels of functional
protein and confer the highest risk for ESKD by age 30
years. The risk is lower with missense or splice site
mutations.25
The estimated risk for ESKD in Alport syndrome varies
with the mode of inheritance. For X-linked Alport syndrome, the clinical phenotype in women differs from that
in men, who have a more severe presentation and universally develop ESKD: X-linked women have up to a 25%
risk for ESKD, whereas X-linked men have a 100%
risk.11,26 Under the reclassification scheme discussed later,
women with X-linked inheritance, previously seen only as
carriers, would have Alport syndrome diagnosed and be
considered to have an appreciable risk for disease progression.11 Among persons with autosomal recessive inheritance, both sexes experience 100% risk for progression
to ESKD.11,27 Among persons with autosomal dominant
inheritance, the estimated risk for ESKD is ≥20% for those
with risk factors for progression (proteinuria, FSGS, GBM
thickening and lamellation, sensorineural hearing loss,
evidence of progression in patient, or family genetic
modifiers) and <1% in the absence of these risk factors.11
Digenic inheritance affecting COL4A3, COL4A4, and COL4A5
genes have a variable estimated risk for ESKD depending on
the affected genetic state: up to 100% for COL4A3 and
Kidney Med Vol 2 | Iss 5 | September/October 2020
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Table 1. New Classiﬁcation Scheme Categorizes Genetic
Diseases of COL4A3, COL4A4, and COL4A5 Into 3 Types of
Alport Syndrome: X-linked, Autosomal, and Digenic
Affected
Inheritance Gene(s)
COL4A5
X-linked

Autosomal

COL4A3 or
COL4A4

Digenic

COL4A3,
COL4A4, and
COL4A5

Allelic State
Hemizygous
(males)
Heterozygous
(females)
Homozygous or
compound
heterozygous
Heterozygous
Variable

Mutation
Phenotype
NA
NA
Recessive
Dominant

Abbreviation: NA, not applicable.
Data from Kashtan et al.11

COL4A4 mutations in trans simulating autosomal recessive
transmission, up to 20% for COL4A3 and COL4A4 mutations
in cis simulating autosomal dominant transmission, and up
to 100% of affected men for mutations in COL4A5 and
either COL4A3 or COL4A4 in which the inheritance pattern
does not simulate any Mendelian transmission (Table 1).11
Progression to ESKD in affected persons follows predictable stages: (1) asymptomatic glomerular hematuria
ranging from microscopic to gross hematuria, (2) microalbuminuria, and (3) declining glomerular filtration rate
(GFR) and ultimately ESKD.28 There is a possibility that as
COL4 mutations are identified more commonly in kidney
disorders such as FSGS, progression may not be as predictable because some patients may present with primary
proteinuric manifestations, as is the case with FSGS.29,30
It is important to note that the risk for progression to
ESKD is based on current estimates. With greater frequency
of genetic testing, our understanding of the risks for
progression will improve as more individuals with autosomal dominant Alport syndrome are identified and are
not either misdiagnosed or given a nonspecific diagnosis
of CKD. Recent Expert Consensus Guidelines recommend
genetic testing for confirmation of an Alport syndrome
diagnosis.15 Genetic testing is more sensitive and specific
than kidney biopsy and is recommended as the gold
standard. In patients with suspected Alport syndrome,
high-throughput–targeted next-generation sequencing
technologies with a customized panel for testing all 3
Alport genes—COL4A3, COL4A4, and COL4A5—together
can identify up to 95% of pathogenic COL4A variants.1,15
Toward that end, recent gene sequencing studies consistently demonstrate that variants in COL4A3, COL4A4, and
COL4A5 commonly result in sporadic and familial adult
FSGS, which should be identified as Alport syndrome
based on the reclassification proposal.29,30
Extrarenal manifestations of Alport syndrome also
mandate attention. Sensorineural hearing loss for high
frequencies has been observed in patients with Alport
syndrome, with the highest occurrence of 70% in male
Kidney Med Vol 2 | Iss 5 | September/October 2020

patients with X-linked Alport syndrome. Some patients
develop lenticonus, which also occurs most frequently in
X-linked affected men, up to 30% by the fourth decade of
life, a time by which kidney failure, hearing loss, and
retinopathy have already developed.1 However, a lack of
sensorineural hearing loss should not diminish consideration of Alport syndrome in the differential diagnosis.
Most women with progressive CKD due to X-linked Alport
syndrome do not have hearing loss but still have a significant probability of progression to ESKD.26
PROPOSED RECLASSIFICATION OF ALPORT
SYNDROME
As referred to, the Alport Syndrome Classification Working
Group recently proposed a reclassification scheme of genetic disorders of the type IV collagen α345 molecule.11
This proposed classification scheme is based on clinical
and molecular genetic criteria instead of relying solely on
histologic and clinical traits that are sex- and agedependent or potentially modifiable by remote genetic
variants11 or other exposures. By defining individuals
genetically by identifying mutations affecting the type IV
collagen α345 molecule as at risk for progressive kidney
disease, the proposed scheme promotes surveillance of
affected patients and early initiation of nephroprotective
therapy.11
Results from genetic evaluations of patients with CKD
suggest that the proposed reclassification would identify
some patients for whom the cause of kidney disease is
unknown or thought to be other more common conditions (eg, type 2 diabetes and hypertension) as being
affected by Alport syndrome. For example, exome
sequencing analysis in a cohort of 3,315 patients with CKD
yielded a genetic diagnosis in w10% of cases (Fig 2).14
Among patients with a genetic diagnosis, w30% had
COL4A3, COL4A4, or COL4A5 gene mutations.14 Notably, 56
of the 91 (62%) patients in this study with COL4A mutations did not have a clinical diagnosis of either Alport
syndrome or TBMN.14 In a screening analysis for mutations in COL4A3, COL4A4, and COL4A5 in 101 unrelated
patients with a positive history of hematuria—many of
whom (77/101) also had a family history of hematuria,
CKD, or both—80% (81/101) had COL4A mutations.31 Of
these, w20% were autosomal dominant.31 In this study,
the proportion of variations considered as possibly disease
causing in patients with COL4A3 and COL4A4 mutations
was higher than previously reported and prompted the
suggestion that the frequency of autosomal Alport syndrome and particularly autosomal dominant disease was
higher than previously believed.31
UNMET NEEDS IN THE MANAGEMENT OF
ALPORT SYNDROME
The goal of kidney-related therapy in Alport syndrome
is to delay progression to ESKD. Angiotensin-converting
641
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Figure 2. COL4A3, COL4A4, and COL4A5 mutations represent 30% of patients with a genetic cause of chronic kidney disease
(CKD).14 Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) were the most prevalent monogenetic
causes of CKD detected in a recent exome sequencing analysis of patients with CKD. Notably, 56 of the 91 patients (62%) identiﬁed
by mutational screening as having Alport syndrome did not have a clinical diagnosis of Alport syndrome. Abbreviations: FSGS, focal
segmental glomerulosclerosis; GN, glomerulonephritis; HTN, hypertension; NOS, not otherwise speciﬁed; PKD, polycystic kidney
disease; TBMN, thin basement membrane nephropathy.

enzyme (ACE) inhibition has been shown to reduce
proteinuria in patients with Alport syndrome, delay
kidney failure in mice with Alport syndrome, and be of
value in delaying kidney failure in humans. According to
the European Alport Registry, data collected from several
generations of Alport families (n = 283) during 2 decades demonstrate that early treatment with ACE inhibitors delayed kidney failure and enhanced life
expectancy in a time-dependent manner, supporting the
need for early diagnosis and nephroprotective treatment.32 A separate study of heterozygous carriers of Xlinked Alport syndrome and a subgroup of patients with
what has been referred to as TBMN due to heterozygous
autosomal recessive Alport mutations (n = 234) also
demonstrated that inhibition of the renin-angiotensinaldosterone system (RAAS) significantly delayed the
onset of ESKD in these subpopulations.33
Inhibition of the RAAS has been consistently
shown to attenuate the loss of kidney function
among patients with many glomerular diseases, with
more pronounced benefits observed among patients
with higher levels of proteinuria or albuminuria.34,35
Intensive lowering of systolic blood pressure, as
tested in the Systolic Blood Pressure Intervention
Trial (SPRINT), was shown to substantially reduce
the incidence of death and cardiovascular events in
patients with and without CKD, although there were
too few events of CKD progression to determine
whether lower systolic blood pressure targets resulted
in higher or lower rates of progressive CKD or
ESKD.36 The Effect of Strict Blood Pressure Control
and ACE Inhibition on the Progression of Chronic
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Renal Failure in Pediatric Patients (ESCAPE) trial
demonstrated that more intensive blood pressure
management in pediatric patients with CKD from any
cause significantly prolonged the time until a 50%
decline in GFR or progression to ESKD.37
However, despite treatment with RAAS inhibitors, there
is progressive loss of kidney function in patients with
Alport syndrome, as reflected by a mean decline of
approximately −4 mL/min per year in estimated GFR at
72 weeks, as demonstrated by A Natural History Study to
Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients (ATHENA),
a noninterventional (observational) global multicenter
study of 250 patients with Alport syndrome.38 In this regard, treatment with RAAS inhibitors slows but does not
stop the progression to kidney failure in Alport syndrome
and emphasizes the urgent need for the discovery of new
treatment options.39
There are also a number of important disease management needs in addition to kidney-specific treatment.
For instance, hearing aids are usually very effective for
patients with concomitant hearing loss.40 As with any
hereditary disease, psychosocial support for the patient
and family is essential in the management of Alport
syndrome.40 In a study examining the psychosocial
impact of Alport syndrome, patients and family members experienced denial, chronic mental suffering,
depressive symptomatology, and anxiety. Families with
Alport syndrome should be encouraged to discuss their
thoughts openly, and the empathy of the clinician as
well as appropriate psychological support are critical to
the process.41
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Figure 3. Activation of resident kidney cells produces proinﬂammatory cytokines and chemokines.51 Chronic inﬂammation is evidenced by activation of resident kidney cells adapting a proinﬂammatory response. These resident cells include endothelial cells,
mesangial cells, podocytes, and tubular epithelial cells. Abbreviations: IFN-ɑ, interferon α; IL-6, interleukin 6; NF-κB, nuclear factor
κ-light-chain-enhancer of activated B cells; TNF, tumor necrosis factor. Adapted by permission from Springer Nature. Nat Rev Immunol. The immune system and kidney disease: basic concepts and clinical implications. Kurts C, Panzer U, Anders HJ, Rees AJ.
Copyright 2013.

ROLE OF CHRONIC INFLAMMATION AND
METABOLIC DYSFUNCTION IN THE
PROGRESSION OF ALPORT SYNDROME
An important unmet need in Alport syndrome, in addition
to the reclassification and management consideration discussed thus far, is to better understand emerging pathogenic
mechanisms in the progression of the disease. Chronic
inflammation and metabolic dysfunction have been identified as key pathogenic mechanisms in patients with a variety
of kidney disorders, including TBMN (proposed to be
Alport syndrome according to the reclassification).42 In a
comprehensive pathway analysis of CKD that included human kidney biopsies of 157 diverse patients with CKD
related to 9 different disorders including TBMN,11 chronic
inflammation in both the tubulointerstitial and glomerular
compartments and metabolic dysfunction were considered
to be the final common pathways in the pathogenesis of
CKD progression that correlate with reduced estimated
GFR.42 This analysis demonstrated clear similarities in the
inflammatory mechanisms involved in various forms of
CKD, including TBMN.11,42 The anti-inflammatory nuclear
factor erythroid 2–related factor 2 (Nrf2) pathway was
identified as the pathogenic link between inflammatory and
metabolic pathways in the progression of multiple types
of CKD.42
Progression of CKD has been suggested to occur
through a final common pathway of chronic inflammation
leading to renal fibrosis.43 Acute inflammation is a natural
immune response to kidney injury44 and plays a critical
Kidney Med Vol 2 | Iss 5 | September/October 2020

role in renal cell repair following damage. Chronic
inflammation is a result of inadequate downregulation of
proinflammatory gene transcription and signaling.44-48
Activation of inflammatory pathways may also interfere
with the normal response of Nrf2-associated pathways to
oxidative stress. For example, it has been shown that a
subunit of the proinflammatory transcription factor,
nuclear factor κ-light-chain-enhancer of activated B cells
(NF-κB) p65 represses the Nrf2-antioxidant response
element pathway at the transcriptional level.49
Role of Resident Kidney Cells in Chronic
Inﬂammation
Although acute inflammation is marked by infiltrating
white blood cells, including neutrophils, macrophages,
dendritic cells, and T and B lymphocytes,50 chronic
inflammation is characterized by activation of resident
kidney cells that develop a proinflammatory response
(Fig 3).51 These resident kidney cells include endothelial
cells, mesangial cells, podocytes, and tubular epithelial
cells, which proliferate and produce proinflammatory
chemokines and cytokines that subsequently recruit
macrophages to damaged tissue.
This further perpetuates the cycle of chronic inflammation
that leads to renal fibrosis.9,48,51 Typically, the endothelial
cells of the glomerulus are uniquely adapted for selective
filtration and permeability.52 Mesangial cells play a role in
glomerular contraction, modulating the filtration coefficient—the permeability or conductivity of the filtration
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barrier denoted by the filtration coefficient—and the filtration surface area, which help regulate GFR.53 In the setting of
oxidative stress and inflammation, dynamic and long-term
actions are provoked, leading to GFR decline.53 These
dynamic actions include the reactive oxygen species
(ROS)-induced mesangial cell contraction and glomerular
endothelial dysfunction due to decreased nitric oxide
bioavailability, causing reduction of the filtration coefficient.53 Podocyte foot contraction and effacement are
adaptive responses to inflammation and oxidative stress that
may be instituted to prevent podocyte loss.54 As a consequence, the integrity of glomerular filtration is apparently
reduced, owing to the denudation of the GBM54 and manifest
by reduced GFR, some proportion of which appears to be
reversibly recoverable with amelioration of the inflammatory
signaling to mesangial cells and podocytes.55,56
In Alport syndrome, the altered composition of the GBM
renders the glomerulus susceptible to damage caused by
biomechanical stress, which induces proteinuria and damages the podocytes leading to increased albumin uptake by
the proximal tubules.57 The glomerular damage further
prompts a sustained inflammatory response leading to
fibrosis.45,58 In CKD, myofibroblasts play a key role in the
development of fibrosis; a variety of molecular signals and
processes contribute to their formation and activation.
Factors responsible for the injurious nature of myofibroblasts include the activation of endothelial cells by vascular
endothelial cell growth factor released from injured interstitial fibroblasts, renal pericytes, fibrocytes, and tubular
epithelial cells, which produce platelet-derived growth factor
(PDGF) and transforming growth factor β (TGFβ).59-61
Pericytes subsequently detach from endothelial cells, proliferate, spread, and migrate into the interstitium. These events
result in unstable vasculature, capillary loss, interstitial matrix
expansion, and contraction of tissue architecture resulting in
a phenotypic conversion of pericytes to myofibroblasts.59
Subsequently, myofibroblasts synthesize ECM components,
leading to excessive collagen accumulation and fibrosis.45,58
The consequent fibrosis results in irreversible loss of kidney
function.9,28,45,47,62-64
Proinﬂammatory Role of NF-κB
The transcription factor NF-κB is a regulator of proinflammatory genes that orchestrates hundreds of inflammatory cytokines and mediators.65 NF-κB promotes the
expression of tumor necrosis factor α (TNF-α) and other
cytokines that activate renal cells and recruit macrophages
to damaged tissue, which contribute to progressive
glomerulosclerosis.9,43,48,65,66 In mouse models of Alport
syndrome, TNF-α messenger RNA expression was
increased in the mesangium and podocytes of the COL4A3
mice glomeruli as the disease progressed, demonstrating
that TNF-α contributed to the etiopathogenesis of progressive glomerulosclerosis.67
NF-κB also increases TGFβ expression, which promotes
transformation of epithelial and mesangial cells into
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fibroblasts and myofibroblasts resulting in fibrosis.9,48
TGFβ1 and connective tissue growth factor, also known
as cellular communication network factor 2, contribute to
the altered glomerular structural and functional properties
of the Alport syndrome GBM, which is characterized by
irregular thickening, splitting, and increased permeability.9 TGFβ1 and platelet-derived growth factor are also
important mediators of interstitial fibrosis, with TGFβ1
upregulation occurring in nearly every type of CKD and
resulting in interstitial ECM accumulation, which contributes to functional loss.68
Additional proinflammatory cytokines that are activated
in an X-linked Alport syndrome mouse model include
interleukin 6 (IL-6) and IL-1β.69 There is evidence both
in vitro (cultured podocytes) and in vivo (through hypertension induction in mice) that the altered GBM in
mouse models of Alport syndrome induced the production
of IL-6.70 Structural changes promoted by these mediators
contribute to a progressive decline in GFR that is characteristic of Alport syndrome and other forms of CKD.71-73
Anti-Inﬂammatory Role of Nrf2
Nrf2 regulates the expression of specific genes that are
involved in cytokine production and protection from
oxidative damage that is triggered by injury and inflammation.74 A cytosolic inhibitor known as kelch-like ECHassociated protein 1 (Keap1) retains Nrf2 in the cytoplasm
until disease triggers activate Nrf2 dissociation from Keap1,
allowing nuclear translocation.74,75 As shown in Figure 4,
under conditions of chronic inflammation and oxidative
stress, electrophiles emerge and alter the conformation of
Keap1 by directly adducting to the specific sensor cysteine
residues in Keap1.76 Because this modification inactivates
the interaction between Keap1 and Nrf2, Nrf2 avoids
degradation in cells exposed to oxidative stress. Stabilized
and newly synthesized Nrf2 translocates into the nucleus,
where it activates transcription of its target genes by binding
to specific recognition sequences, such as antioxidant
response elements as Nrf2-small musculoaponeurotic
fibrosarcoma heterodimers. Target genes of Nrf2 transcriptional regulation contain antioxidant response elements—the Nrf2 response elements—in their promoter
region.76 As a result, Nrf2 induces gene transcription of
anti-inflammatory and antioxidant mediators. Nrf2 also
directly suppresses the expression of proinflammatory
cytokine genes by binding to their promoters and inhibiting
transcription.77 Extensive biochemical, biophysical, and
structural analyses of the Keap1-Nrf2 interaction have
demonstrated the central role of this system in protection
from oxidative and electrophilic stress.78 Further, in vivo
experiments have validated the functional relationship between Keap1 and Nrf2 by demonstrating that phenotypes of
Keap1-null mice are attributable to the constitutive stabilization of Nrf2.79-81 Thus, the Keap1-Nrf2 system plays a
key role in resolving inflammation by decreasing oxidative
damage and inhibiting proinflammatory NF-κB signaling.82
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Figure 4. Molecular mechanisms of the nuclear factor erythroid 2–related factor 2 (Nrf2)-Keap1 (kelch-like ECH-associated protein
1) system.76 Nrf2 is a transcription factor that regulates the expression of hundreds of genes involved in the antioxidant response,
metabolism and lipid regulation, and mitochondrial function. A cytosolic inhibitor, Keap1, retains Nrf2 in the cytoplasm until activated
by disease triggers. Abbreviations: ARE, antioxidant response element; Cys, sensor cysteine residues; Ub, ubiquitin. Reproduced
with permission. Nezu M, Suzuki N, Yamamoto M. Targeting the KEAP1-NRF2 system to prevent kidney disease progression. Am
J Nephrol. 2017;45(6):473-483. Copyright © 2017 Karger Publishers, Basel, Switzerland.
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Results from studies of experimental animals support
the importance of Nrf2 in controlling inflammation in
CKD. Nrf2-knockout mice fed a high-glucose diet rapidly
develop diabetic nephropathy.83 Impaired Nrf2 signaling
in conjunction with NF-κB activation has also been shown
to promote inflammation and oxidative stress in a mouse
5/6 nephrectomy (remnant kidney) model.84 Studies in
experimental animals have also indicated that Nrf2 activation may protect against fibrosis. Unilateral ureteral
obstruction in mice results in a rapid nuclear accumulation
of Nrf2, downregulation of Keap1, and induction of Nrf2dependent genes, which prevent increased levels of ROS
markers. However, longer-term obstruction results in a
progressive reduction in nuclear Nrf2 and increased
oxidative stress, inflammation, fibrosis, and tubular damage.85 In addition, examples from the animal kingdom
imply that antioxidant defense mechanisms with enhanced
Nrf2 expression have, over millennia, evolved to protect
species during extreme environmental conditions.86
Results from multiple studies in patients have also indicated that Nrf2 is involved in kidney disease.83 Biopsy of
kidney tissues from patients with diabetic nephropathy
demonstrated high levels of glucose-induced ROS in
mesangial cells and activation of Nrf2 and downstream
genes.87 Immunohistochemical results from Jiang et al87
demonstrated that Nrf2 was expressed at low levels in
normal glomeruli and was upregulated in glomeruli from
patients with diabetic nephropathy. In contrast, an analysis of
fasting plasma and urine samples from 120 healthy controls
and 180 adult patients with stages 4-5 CKD showed activation of NF-κB and upregulation of proinflammatory and prooxidant messenger RNA and protein expression in patients
with CKD, as well as downregulation of the Nrf2-associated
antioxidant gene messenger RNA and protein expression.88
A separate study investigated the Nrf2 target gene
NAD(P)H: quinone oxidoreductase 1 (NQO1) as a readout
parameter for Nrf2 activity in monocytes of 63 patients
with CKD compared with 16 healthy controls. This study
revealed a 3- to 4-fold increase in NQO1 gene expression in
patients with stages 1-5 CKD (n = 29), with less robust
upregulation in stage 5 dialysis patients with advanced
uremia (n = 34).89 These studies demonstrate how Nrf2
may be upregulated in response to ROS and damage in
early stages of kidney disease but may become suppressed
as the disease progresses and inflammation increases. In
this regard, it is possible that variability in results with
respect to Nrf2 expression in CKD may be related to the
stage of disease.
Given that Nrf2 is a key regulator of the anti-inflammatory
pathway in CKD and its activation can reduce the inflammatory cascade, prevent fibrosis, and restore kidney function,
it is an attractive target for novel therapies.
CONCLUSIONS
Several observational studies suggest that disorders of type
IV collagen, the collagen that is defective in Alport
646

syndrome, may play a central role in CKD in a much larger
proportion of the population than previously believed.
More detailed evaluation of these variants of classic Alport
syndrome are required to improve our understanding of
the role of type IV collagen abnormalities in progressive
CKD. Given the link between type IV collagen abnormalities and kidney inflammation and fibrosis, there is
renewed interest in targeted anti-inflammatory therapies in
Alport syndrome and other forms of progressive CKD.
Human kidney biopsy samples suggest that the antiinflammatory Nrf2 pathway is operative in Alport syndrome, as well as other conditions leading to progressive
CKD, but that its activity may be insufficient to blunt
chronic inflammation. Thus, therapeutic agents that
favorably modify the Nrf2 pathway have the potential to
attenuate, arrest, or reverse the expected loss of kidney
function in adult and pediatric patients with Alport
syndrome.
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